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Abstract 
The role of interleukin-6 (IL-6) in rheumatoid arthritis patients associated with anemia stilled unclear because of 
the limited researches. Therefore we evaluated the levels of IL-6 in rheumatoid arthritis patients associated with 
anemia.30 patients with rheumatoid arthritis and anemia (23 males and 7 females), 30 patients with rheumatoid 
arthritis only (18 males and 12 females) and 30 healthy control groups (14 males and 16 females) were enrolled 
in our study, the levels of IL-6 cytokine were measured by enzyme-linked immunoabsorbent assays (ELISA), 
rheumatoid factor test (RF), Anti-CCP antibody test, Hematocrit %, Hb level g/dL for all cases also was assessed 
and statistical analysis of the data was then processed. The levels of IL-6 in patients with rheumatoid arthritis 
and anemia was ranged between 78 and 122 pg/ml also the second group, patients with rheumatoid arthritis only 
was ranged between 20 and 59 pg/ml, and control free disease was ranged between 1 and 10 pg/ml. Also our 
results showed the statistical significance  between patients with rheumatoid arthritis and anemia and patients 
with rheumatoid arthritis only with (CI 95%)at (-43.355- -36.112), T-test (0.000),  patients with rheumatoid 
arthritis and anemia and  control free disease with (CI 95%)at (-100.364- -89.636), T-test (0.000) and patients 
with rheumatoid arthritis only and control free disease with (CI 95%)at (-62.241- -48.293), T-test (0.000) 
respectively. We concluded that IL-6 cytokine play important role in rheumatoid arthritis with anemia. 
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Introduction 
Rheumatoid arthritis (RA) is the greatest mutual autoimmune inflammatory arthritis in adults (Helmick CG et al., 
2008). Rheumatoid arthritis (RA) primarily touches the synovial joints, resulting in pain, deformity and eventual 
functional limitation, causing substantial morbidity and accelerated mortality (Cush et al., 2007). The condition 
also has widespread extra articular manifestations including vacuities, inflammation in the heart and lungs and 
peripheral neuropathy. The disease confers an increased risk of many other diseases including cardiovascular 
disease, pulmonary dysfunction, renal disorders and intestinal pathologies, along with a significantly increased 
risk of premature death (NCCCC, 2009).  Anemia of chronic disease is immune driven; cytokines and cells of 
the reticuloendothelial system induce changes in iron homeostasis, the proliferation of erythroid progenitor cells, 
the production of erythropoietin, and the life span of red cells, all of which contribute to the pathogenesis of 
anemia . Recent studies have demonstrated serum inhibition of in vitro erythropoiesis in adult and juvenile 
patients with chronic arthritis. (Yap and Stevenson, 1994: Gordeuk et al., 2001). Moreover, tumor cells can 
produce proinflammatory cytokines and free radicals that damage erythroid progenitor cells (Weiss, 2002: 
Means 2003: Sullivan et al., 1998). Bleeding episodes, vitamin deficiencies (e.g., of cobalamin and folic acid), 
hypersplenism, autoimmune hemolysis, renal dysfunction, and radio- and chemotherapeutic interventions 
themselves can also aggravate anemia (Rodriguez et al., 2001: Groopman and Itri, 1999). Anemia is frequently 
seen in patients with active rheumatoid arthritis (RA) (Mowat, 1971). Many causes of anemia are associated with 
RA, such as deficiencies of iron (Hansen et al., 1983). Interleukin-6 (IL-6) is a monokine with biological 
activities related to inflammatory responses (Geiger, 1988: Nijsten et al., 1987). IL-6 levels were elevated in 
serum and synovial fluid of patients with active RA (Swaak et al.,1988: Houssian et al.,1988). About the effects 
of IL-6 on bone marrow only few data exist (Leafy et al., 1988). In this study, we measured the serum IL-6 
levels in patients diagnosed with both rheumatoid arthritis and anemia and correlated with patients diagnosed 
with rheumatoid arthritis only.   
 
Materials and Methods 
In this study, 30 patients with rheumatoid arthritis and anemia (23 males and 7 females) with an age mean ± SD 
(68.43± 8.516) family history (6 positive/24 negative), rheumatoid factor test (RF) (13 positive/17 negative), 
Anti-CCP antibody test (30 positive/ 0 negative), Hematocrit % mean ± SD (27.73 ± 3.005), Hb level g/dL mean 
± SD (8.910± 1.0008), 30 patients with rheumatoid arthritis only (18 males and 12 females) with an age mean ± 
SD (66.57± 13.206) family history (2 positive/28 negative), rheumatoid factor test (RF) (10 positive/ 20 
negative), Anti-CCP antibody test (30 positive/ 0 negative), Hematocrit % mean ± SD (45.70 ± 3.239), Hb level 
g/dL mean ± SD (14.897± 1.0826), and 30 healthy control groups (14 males and 16 females)  with an age mean 
± SD (1.53± 0.507) ,were recruited at Alkindy teaching hospital, Baghdad, Iraq. Patients with RA [diagnosed 
based on American Rheumatism Association (ACR) 1987 Criteria (Arnett et al. 1988). The study subjects were 
informed about the purpose of the study, and written consent was taken from each of them. Ethical approval was 
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obtained from the Local Ethics Committee. 
 
Peripheral blood samples 
Peripheral blood samples for laboratory measurements were drawn immediately. Venous blood was collected 
into sterile EDTA tubes and analyzed the same day for hemoglobin measurement. Anemia was defined as the 
reduction in Hematocrit levels below 35% and    the reduction of hemoglobin below 12.0 g/dL. Peripheral blood 
was also drawn into sterile tubes, allowed to clot for 30 minutes, and spun at room temperature for 20 minutes at 
2500 rpm; sera were aliquoted and stored at -70°C for interleukin 6 (IL-6) quantification by means of enzyme-
linked immunosorbent assay (ELISA; Quantikine; R & D Systems Europe, Abingdon, England), IL-6 ELISA Kit 
was (AviBion Human IL-6 ELISA Kit, Orgenium Laboratories, Finland). Serum concentration of IL-6 was 
determined based on a standard concentration curve.   
 
Statistical analysis 
A computer statistical program was used (SPSS vs. 19) to analyze the data. Patients and control group pa-
rameters and the relations between the parameters were compared using “Paired Samples T” confidence interval 
(95% CIs) were calculated for different studied parameters. The confidence interval (CI) at 95% was used to 
describe the amount of uncertainty associated with the samples. Mean values and standard deviations were 
presented. P value less than 0.05 was considered as statistically significant. 
 
Results  
The three groups were compared to assess the level of IL-6 cytokine as described, the first group (patients with 
rheumatoid arthritis and anemia) with IL-6 concentrations ranged between 78 and 122 pg/ml and mean ± SD 
(99.47± 13.910) as shown in table 1, also the second group (patients with rheumatoid arthritis only) with IL-6 
concentrations ranged between 20 and 59 pg/ml and  mean ± SD (44.20± 10.015) as shown in table 2, and the 
last group was (control free disease) with IL-6 concentrations ranged between 1 and 10 pg/ml and mean ± SD 
(4.47± 2.501) as shown in table 3. Also the Paired Samples T test shown statistical significance between patients 
with rheumatoid arthritis and anemia and patients with rheumatoid arthritis only with (CI 95%)at (-43.355- -
36.112), T-test (.000),  patients with rheumatoid arthritis and anemia and  control free disease with (CI 95%)at (-
100.364- -89.636), T-test (.000) and patients with rheumatoid arthritis only and control free disease with (CI 
95%)at (-62.241- -48.293), T-test (.000) respectively as shown in table 4.       
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Table 1: Showed the frequency and Percent of IL- 6 cytokine levels among patients with rheumatoid arthritis and 
anemia 
 IL- 6 cytokine level pg/ml Frequency Percent 
 78 3 10.0 
79 1 3.3 
87 3 10.0 
89 2 6.7 
91 2 6.7 
93 2 6.7 
94 1 3.3 
99 2 6.7 
103 3 10.0 
109 1 3.3 
110 2 6.7 
111 1 3.3 
112 1 3.3 
113 1 3.3 
117 1 3.3 
118 1 3.3 
120 1 3.3 
121 1 3.3 
122 1 3.3 
Total 30 100.0 
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Table 2: Showed the frequency and Percent of IL- 6 cytokine levels  among patients with rheumatoid arthritis 
only 
 IL- 6 cytokine level pg/ml Frequency Percent 
 20 1 3.3 
23 1 3.3 
32 1 3.3 
33 2 6.7 
34 1 3.3 
37 1 3.3 
39 2 6.7 
40 1 3.3 
42 2 6.7 
43 3 10.0 
44 1 3.3 
47 1 3.3 
48 3 10.0 
51 1 3.3 
52 1 3.3 
53 2 6.7 
55 2 6.7 
56 1 3.3 
57 2 6.7 
59 1 3.3 
Total 30 100.0 
 
Table 3: Showed the frequency and Percent of IL- 6 cytokine levels among control  
 IL- 6 cytokine level pg/ml Frequency Percent 
 1 2 6.7 
2 4 13.3 
3 9 30.0 
4 3 10.0 
5 2 6.7 
6 3 10.0 
7 3 10.0 
8 2 6.7 
10 2 6.7 
Total 30 100.0 
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Table 4: Showed the Paired Samples T test for IL- 6 cytokine levels among the three groups 
 
Paired Differences t 
Sig. (2-
tailed) 
95% Confidence Interval 
Of  the Difference 
-22.439 .000 
Lower Upper 
Pair 
1 
patients with rheumatoid arthritis and anemia  -  
patients with rheumatoid arthritis only 
 
-43.355 
 
-36.112 
Pair 
2 
patients with rheumatoid arthritis and anemia   -  
control free disease 
-100.364 -89.636 -36.223 .000 
Pair 
3 
patients with rheumatoid arthritis only  -  control 
free disease 
-62.241 -48.293 -16.208 .000 
*significant at P≤0.05 
 
Discussion 
Cytokines are small, biologically highly active proteins that regulate the growth, function, and differentiation of 
cells and help steer the immune response and inflammation (Thomson A, 1998).  IL-6 is a pleiotropic, 
immunomodulatory cytokine produced by a variety of cell types, including fibroblasts, endothelial c ells, 
monocytes and both benign and malignant lymphocyte s of B and T cell origin (Akira et al., 1993). It is a 
multifunctional cytokine, which plays a key role in the differentiation and growth of haematopoietic cells, B-
cells, T-c ells, keratinocytes, neuronal cells osteoclasts and endothelial cells (Baue and He rrmann, 1991). The 
role of IL-6 cytokine in the pathogenesis of RA and their significance in clinical monitoring of the disease 
already mentioned in many studies (Koch et al., 1995: Brennan et al., 1995). In this disease the articular synovial 
membrane is infiltrated w ith inflammatory cells diffusing into the synovial fluid. The inflammatory process 
spreads from the synovial membrane to the cartilage and bone tissue causing their damage (Koch et al., 1995). 
Otherwise the pathogenesis of the anaemia associated with rheumatoid disease is unclear (Cartwright and Lee, 
1979: Vreugdenhil et al., 1990). Recent studies have demonstrated serum inhibition of in vitro erythropoiesis in 
adult and juvenile patients with chronic arthritis (Dainiak et al., 1980: Prouse et al., 1987). Inhibition of 
erythropoiesis corresponded with the severity of the anaemia (Prouse et al., 1987). And with inflammatory 
activity (Dainiak et al., 1980: Prouse et al., 1987).  According our results that a proved gradually elevation of IL-
6 cytokine level among control and patients with rheumatoid arthritis and patients with both rheumatoid arthritis 
and anemia as mentioned previously, (Vreugdenhil et al.) Noticed that the serum IL-6 was elevated in anemia of 
chronic disease ACD and it correlated well with parameters of disease activity such as erythrocyte sedimentation 
rate and C-reactive protein. IL-6 addition to bone marrow cultures had inconsistent effects while anti-IL-6 
addition resulted in impaired erythroid colony growth, suggesting stimulatory effects of IL-6 produced in the 
medium, which may be masked by simultaneous production of cytokines with suppressive effects. It was 
concluded that elevated serum IL-6 in ACD reflects disease activity. It probably plays no pathogenetic role in 
ACD. Its stimulatory effects on erythroid growth might counteract suppressive effects of other interleukins 
(Vreugdenhil et al., 1990). Some potent inhibitors of erythropoiesis have been described by(Panay, G.S), 
suggested that several cytokines like TNFα, IL-1, IL-6, IL- 8, IFN β and IFNy which mediate chronic 
inflammation in rheumatoid arthritis (RA) (Panay,1993). In conclusion, according to the mechanism and the role 
of IL-6 in rheumatoid arthritis and anemia we suggested that, there are strong associations between the levels of 
IL-6 with rheumatoid arthritis and anemia.   
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